Mixed Protamine Zinc Recombinant Insulin Lispro Injection(25R)（Tonghua Dongbao）

精蛋白锌重组赖脯胰岛素(25R)（通化东宝）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMixed Protamine Zinc Recombinant Insulin Lispro Injection(25R)（Tonghua Dongbao）
Drug Alias Nameinsulin lispro protamine suspension biosimilar精蛋白锌重组赖脯胰岛素(25R)protamine/zinc/insulin lispro
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonistsInsulin ligand
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTonghua Dongbao Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTonghua Dongbao Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A